Faecal microbiota transplantation for treatment of recurrent or refractory Clostridioides difficile infection in Hong Kong

Rashid N. Lui, Sunny H. Wong, Louis Ho Shing Lau, Tt Chan, Kitty Cheung, Amy Yl Li, Ml Chin, Whitney Tang, Jessica Y. L. Ching, Kelvin Ly Lam, Paul K.s. Chan, Justin Cy Wu, Joseph J.�y. Sung, Francis K.l. Chan, Siew C. NgHong 2019 · DOI

Abstract

Our results confirm that FMT is a safe, efficacious, and feasible intervention for patients with refractory or recurrent CDI in Hong Kong. Given the increasing disease burden and the lack of effective alternatives in Hong Kong for difficult-to-treat cases of CDI, we recommend that a territory-wide FMT service be established to address increasing demand for this treatment.

Introduction

Clostridioides difficile infection (CDI) represents a significant global healthcare challenge, typically arising when antibiotic use disrupts the gut microbiome's natural balance. In Hong Kong, the situation is increasingly urgent, with CDI incidence rising by 26% annually between 2006 and 2014. For patients suffering from recurrent or refractory cases—where standard therapies like vancomycin fail—there is a critical treatment gap. This study evaluates the efficacy and safety of Faecal Microbiota Transplantation (FMT) within the Hong Kong healthcare context.

Methods

Researchers conducted a single-centre, retrospective study at an academic hospital, reviewing 24 consecutive cases of difficult-to-treat CDI between 2013 and 2018. The protocol evolved from using screened relatives as donors to utilizing a "Healthy Donor Stool Biobank" established by the Chinese University of Hong Kong. This biobank provided pre-screened frozen stools, which underwent rigorous testing for a wide array of pathogens, including multidrug-resistant organisms. FMT was administered via three primary routes: feeding tubes (45.8%), esophagogastroduodenoscopy (33.3%), or colonoscopy (25.0%), with most patients receiving a standardized dose of 50g of FMT product.

Results and Patient Profile

The study cohort consisted of 24 patients with a median age of 70 years. This was a high-risk group, with over 80% having been recently hospitalized or residing in long-term care facilities. Comorbidities were prevalent, including hypertension, inflammatory bowel disease, and stroke.

Patient characteristics, administration routes, and clinical outcomes.

Primary efficacy was high, with 21 out of 24 patients (87.5%) achieving resolution of diarrhea without relapse within 8 weeks of a single FMT. The three patients who did not respond to the initial treatment underwent a second FMT, and all three subsequently recovered, resulting in a 100% ultimate success rate for the cohort. Safety outcomes were excellent; there were no deaths within 30 days and no serious adverse events attributable to the procedure. Minor complications were limited to transient abdominal discomfort (12.5%) and bloating (4.2%).

Discussion

FMT functions as an ecological restoration, replenishing microbial diversity to eliminate the niches that C. difficile exploits. Notably, the 87.5% success rate observed in Hong Kong is remarkably consistent with results reported in Western literature, suggesting that FMT's efficacy is robust across different dietary and environmental backgrounds. The transition to a centralized stool biobank represents a major advancement in feasibility, allowing for "off-the-shelf" treatment and rapid intervention.

Conclusion and Future Directions

While limited by a small sample size and retrospective design, this study confirms that FMT is a safe and highly effective intervention for refractory or recurrent CDI, even in elderly and medically complex populations. To address the rising disease burden, the authors advocate for the establishment of a territory-wide FMT service in Hong Kong. Such a service would involve multidisciplinary teams and a centralized registry to optimize treatment timing and monitor long-term safety.

Summary updated

Abstract

Our results confirm that FMT is a safe, efficacious, and feasible intervention for patients with refractory or recurrent CDI in Hong Kong. Given the increasing disease burden and the lack of effective alternatives in Hong Kong for difficult-to-treat cases of CDI, we recommend that a territory-wide FMT service be established to address increasing demand for this treatment.
BibTeX
@inproceedings{lui2019faecal,
  author = {Rashid N. Lui and Sunny H. Wong and Louis Ho Shing Lau and TT Chan and Kitty Cheung and Amy YL Li and ML Chin and Whitney Tang and Jessica Y. L. Ching and Kelvin LY Lam and Paul K.S. Chan and Justin CY Wu and Joseph J.�Y. Sung and Francis K.L. Chan and Siew C. Ng},
  title = {{Faecal microbiota transplantation for treatment of recurrent or refractory Clostridioides difficile infection in Hong Kong}},
  booktitle = {Hong},
  year = {2019},
  doi = {10.12809/hkmj197855},
}
Figure